Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
8
×
life sciences
medicare
8
×
national
national blog main
national top stories
new york blog main
new york top stories
novartis
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
pfizer
biogen
drug prices
merck
bristol-myers squibb
cancer
celgene
deals
gene therapy
immunotherapy
president trump
What
bio
roundup
drug
new
patients
price
companies
crispr
gene
pharmaceutical
plan
prices
remains
talk
today
acquisitions
advantages
airport
albert
allogene
alzheimer’s
annual
apocalypse
approval
away
bar
becker
beds
biggest
billions
biogen’s
biopharmaceutical
bourla
bringing
brings
cancer
celgene
ceo
ceos
company
Language
unknown
unset
Current search:
biotech
×
novartis
×
" indiana top stories "
×
medicare
×
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More